https://kalivir.com/ https://kalivir.com/kalivir-immunotherapeutics-reports-71-objective-response-rate-in-patients-with-advanced-cutaneous-malignancies-in-phase-1-1b-stealth-001-trial/ 2026-11-06T09:00:00-05:00 https://kalivir.com/kalivir-immunotherapeutics-announces-closing-of-14-million-series-a-extension-financing/ 2026-08-19T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-vet3-tgi-in-combination-with-atezolizumab-tecentriq-in-advanced-solid-tumors/ 2025-11-19T09:00:00-05:00 https://kalivir.com/kalivir-immunotherapeutics-announces-completion-of-first-intravenous-patient-cohort-of-stealth-001-study-evaluating-vet3-tgi-in-patients-with-advanced-solid-tumors/ 2025-10-01T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-completion-of-first-cohort-of-stealth-001-study-evaluating-vet3-tgi-in-patients-with-advanced-solid-tumors/ 2025-05-20T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-details-of-presentation-at-2025-american-association-for-cancer-research-aacr-annual-meeting/ 2025-03-25T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-strengthens-innovation-portfolio-with-issuance-of-three-new-u-s-patents-covering-its-vet-product-candidates/ 2024-11-18T09:00:00-05:00 https://kalivir.com/kalivir-immunotherapeutics-doses-first-patient-in-phase-1-1b-trial-of-vet3-tgi-for-incurable-advanced-solid-tumors/ 2024-10-08T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-appoints-schond-greenway-as-chief-financial-officer/ 2024-09-04T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors/ 2024-07-01T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-appoints-james-m-burke-m-d-as-chief-medical-officer/ 2024-02-21T09:00:00-05:00 https://kalivir.com/kalivir-announces-opening-of-gmp-cleanroom-facility-increasing-manufacturing-capacity-for-oncolytic-viruses/ 2024-01-31T09:00:00-05:00 https://kalivir.com/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-systemic-oncolytic-virus-asp1012-for-phase-i-clinical-trials-for-locally-advanced-or-metastatic-solid-tumors/ 2023-10-24T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-new-in-vivo-data-demonstrating-superior-therapeutic-efficacy-of-vet3-tgi-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting/ 2023-05-19T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-appoints-viral-immunotherapy-researcher-grant-mcfadden-ph-d-to-its-board-of-directors/ 2023-05-10T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-presentation-at-the-american-society-of-gene-cell-therapy-asgct-annual-meeting/ 2023-05-03T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-announces-new-in-vivo-data-demonstrating-potent-therapeutic-activity-for-oncolytic-therapy-vet3-tgi-at-the-american-association-for-cancer-research-aacr-annual-meeting/ 2023-04-17T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-establishes-clinical-and-scientific-advisory-boards/ 2022-12-13T09:00:00-05:00 https://kalivir.com/kalivir-immunotherapeutics-announces-pre-clinical-data-for-oncolytic-therapy-vet3-tgi-at-the-society-for-immunology-of-cancer-sitc-37th-annual-meeting/ 2022-11-10T09:00:00-05:00 https://kalivir.com/kalivir-appoints-industry-veteran-adina-pelusio-as-senior-vice-president-of-clinical-operations-to-lead-clinical-development-pipeline/ 2022-11-01T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-to-present-at-14th-international-oncolytic-virotherapy-conference-iovc/ 2022-10-24T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-to-present-data-on-its-novel-pre-clinical-oncolytic-therapy-vet3-tgi-at-the-society-for-immunology-of-cancer-sitc-annual-meeting/ 2022-10-05T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-enters-into-global-exclusive-licensing-agreement-with-roche-for-novel-oncolytic-viruses/ 2022-05-23T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-closes-series-a-financing/ 2022-03-16T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-strengthens-intellectual-property-position-through-issuance-of-two-u-s-patents/ 2021-11-04T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-appoints-drs-terry-hermiston-and-jon-wigginton-to-board-of-directors/ 2021-06-17T09:00:00-04:00 https://kalivir.com/kalivir-immunotherapeutics-and-astellas-enter-worldwide-exclusive-licensing-agreement-for-development-and-commercialization-of-vet2-l2-novel-oncolytic-virus/ 2020-12-07T09:00:00-05:00 https://kalivir.com/how-stephen-thorne-and-helena-chaye-are-blending-their-talents-to-create-breakthrough-cancer-fighting-therapies/ 2020-01-01T09:00:00-05:00